Article

Clinically actionable UGT1A1 variants in black Zimbabwean cancer patients eligible for irinotecan

2025-11-03

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0e48945d-02d9-5aa9-aeb6-86d1e05a50f4
DOI: 10.12688/verixiv.2312.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinically actionable UGT1A1 variants in black Zimbabwean cancer patients eligible for irinotecanDOI 10.12688/verixiv.2312.1Read

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read

Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations.Semantic proximity Read

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapySemantic proximity Read

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.Semantic proximity Read

PharmGKB summary: very important pharmacogene information for UGT1A1.Semantic proximity Read

<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practiceSemantic proximity Read

UGT1A1 genotyping in patients undergoing treatment with irinotecan.Semantic proximity Read

UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).Semantic proximity Read

Towards UGT1A1 guided irinotecan dosing.Semantic proximity Read

Clinical and pharmacogenetic factors associated with irinotecan toxicitySemantic proximity Read